The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer.
 
Manisha H. Shah
Consulting or Advisory Role - Eisai; Ignyta
Research Funding - Eisai; Loxo; Merck
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Cota Healthcare; Eisai; Goldilocks; Lilly; Regeneron; UpToDate
Research Funding - Plexxikon
 
Bruce Robinson
Consulting or Advisory Role - Eisai; Loxo
Speakers' Bureau - Eisai
Travel, Accommodations, Expenses - Eisai
 
Benjamin J. Solomon
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Loxo; Merck Sharp & Dohme; Pfizer (Inst); Roche/Genentech
Research Funding - Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Veristrat (Biodesix); UpToDate
 
Hyunseok Kang
Honoraria - Cancer Expert Now; Cardinal Health
Consulting or Advisory Role - Bayer; Genentech; GlaxoSmithKline; Ignyta
Research Funding - Elevar Therapeutics (Inst); Exelixis (Inst); Kura Oncology (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Exelixis; Kura Oncology
 
Jochen H. Lorch
Consulting or Advisory Role - Bayer; Eisai; Genentech
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Millennium (Inst); Novartis (Inst)
 
Francis P. Worden
Honoraria - Bayer; Bristol-Myers Squibb; CUE Biopharma; Eisai; LOXO; Merck Sharp & Dohme
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; CUE Biopharma; Eisai; Loxo; Merck; Rakuten Medical
Research Funding - Bristol-Myers Squibb; Eisai (Inst); Lilly; Loxo; Merck (Inst); Oragenics; Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Merck Sharp & Dohme
 
Marcia S. Brose
Honoraria - Bayer
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Eisai; Genzyme; Loxo; Novartis
Research Funding - Bayer (Inst); Blueprint Medicines (Inst); Eisai (Inst); Exelixis (Inst); Loxo (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Sophie Leboulleux
Consulting or Advisory Role - Loxo
Research Funding - Genzyme; Novartis; Sanofi
 
Yann Godbert
No Relationships to Disclose
 
Marie Meurer
No Relationships to Disclose
 
John C. Morris
No Relationships to Disclose
 
Taofeek Kunle Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES
Consulting or Advisory Role - Abbvie; Amgen; ARMO BioSciences; AstraZeneca; Bayer; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; EMD Serono; G1 Therapeutics; HERON; Lilly; Lilly; MedImmune; Merck; Novartis; PharmaMar; Sandoz; Seagen; Takeda; Xcovery
Speakers' Bureau - Abbvie
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Corvus Pharmaceuticals; Fujifilm (Inst); G1 Therapeutics (Inst); Incyte (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst); United Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)
Other Relationship - EMD Serono; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Reflexion Medical
 
Daniel Shao-Weng Tan
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Loxo; Merck; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Oliver Gautschi
Other Relationship - Bayer (Inst)
 
Jyoti D. Patel
Consulting or Advisory Role - Abbvie; AstraZeneca; Takeda Science Foundation
 
Luxi Yang
Employment - Loxo
 
Jennifer Kherani
Employment - Aisling Capital; Aisling Capital; Aisling Capital (I); Aisling Capital (I); Ajax Health; Ajax Health; Ajax Health (I); Ajax Health (I); Loxo; Loxo; Loxo (I); Loxo (I)
Leadership - Ablacon (I); Ablicon; Ablicon (I); Ablicon (I); Ajax Health; Ajax Health; Ajax Health (I); Ajax Health (I); Cortica; Cortica; Cortica (I); Cortica (I); Spirox; Spirox; Spirox (I); Spirox (I); Summus Medical Solutions; Summus Medical Solutions; Summus Medical Solutions (I); Summus Medical Solutions (I); TransEnterix; TransEnterix; TransEnterix (I); TransEnterix (I); Verix; Verix; Verix (I); Verix (I)
Stock and Other Ownership Interests - Ablacon (I); Aclaris Therapeutics; Aclaris Therapeutics; Aclaris Therapeutics (I); Aclaris Therapeutics (I); Adma Pharma; Adma Pharma; Adma Pharma (I); Adma Pharma (I); Aeglea Biotherapeutics; Aeglea Biotherapeutics; Aeglea Biotherapeutics (I); Aeglea Biotherapeutics (I); Aimmune; Aimmune; Aimmune (I); Aimmune (I); Ajax Health; Ajax Health; Ajax Health (I); Ajax Health (I); Arcus Biosciences; Arcus Biosciences; Arcus Biosciences (I); Arcus Biosciences (I); Armgo; Armgo; Armgo (I); Armgo (I); Atreca; Atreca; Atreca (I); Atreca (I); Avrobio; Avrobio; Avrobio (I); Avrobio (I); Bridgebio; Bridgebio; Bridgebio (I); Bridgebio (I); Cidara Therapeutics; Cidara Therapeutics; Cidara Therapeutics (I); Cidara Therapeutics (I); Earlens; Earlens; Earlens (I); Earlens (I); Eidos Therapeutics; Eidos Therapeutics; Eidos Therapeutics (I); Eidos Therapeutics (I); Harmony Biosciences; Harmony Biosciences; Harmony Biosciences (I); Harmony Biosciences (I); Marker; Marker (I); Marker Therapeutics; Marker Therapeutics (I); Medical Knowledge Group; Medical Knowledge Group; Medical Knowledge Group (I); Medical Knowledge Group (I); Nabriva Therapeutics; Nabriva Therapeutics; Nabriva Therapeutics (I); Nabriva Therapeutics (I); Nuvation Bio; Nuvation Bio; Nuvation Bio (I); Nuvation Bio (I); Obseva; Obseva; Obseva (I); Obseva (I); PellePharm; PellePharm; PellePharm (I); PellePharm (I); Pernix (I); Pernix (I); Poseida Therapeutics; Poseida Therapeutics; Poseida Therapeutics (I); Poseida Therapeutics (I); Prolacta Bioscience; Prolacta Bioscience; Prolacta Bioscience (I); Prolacta Bioscience (I); Promentis; Summus Medical Solutions; Summus Medical Solutions; Summus Medical Solutions (I); Summus Medical Solutions (I); Sunesis Pharmaceuticals
Consulting or Advisory Role - Aisling Capital; Ajax Health; Need Company Names
 
Maria E. Cabanillas
Consulting or Advisory Role - Ignyta; Loxo
Research Funding - Eisai; Exelixis; Kura Oncology; Roche/Genentech
 
Lori J. Wirth
Consulting or Advisory Role - Ayala Pharmaceuticals; Bayer; Blueprint Medicines; CUE Biopharma; Eisai; Exelixis; Genentech; Lilly; Loxo; Merck; Rakuten Medical